目的:观察护心康片治疗不稳定型心绞痛(UAP)气虚痰瘀互阻证的临床疗效。方法:将75例UAP气虚痰瘀互阻证患者随机分为治疗组38例和对照组37例。治疗组在常规西药治疗基础上加服护心康片,对照组在常规西药治疗基础上加服通心络胶囊,疗程均为4周,比较两组临床疗效。结果:综合疗效总有效率治疗组为92.11%,对照组为75.68%,两组比较,差异有统计学意义(P〈0.05);在改善心绞痛症状、中医证候和血脂的LDL-C和HDL-C水平方面,治疗组均优于对照组,差异均有统计学意义(P〈0.05)。结论:护心康片治疗UAP气虚痰瘀互阻证疗效显著,能有效缓解临床症状,提高调节血脂功效。
Objective: To observe the clinical efficacy of Huxinkang tablets in the treatment of unstable angina pectoris (UAP)with qi deficiency and phlegm stasis syndrome. Methods: A total of 75 UAP patients with qi deficien- cy and phlegm stasis syndrome were randomly divided into treatment group( n = 38 ) and control group( n = 37 ). The treatment group was given Huxinkang tablets in addition to the conventional Western medicine treatment, while the control group was given Tongxinluo capsules in addition to the conventional Western medicine treatment. The course of treatment was 4 weeks for both groups. After treatment.the clinical outcomes of the two groups were compared.Results: There was a significant difference in overall response rate between the treatment group and the control group(92. 11% vs 75.68% ,P 〈 0. 05 ). The treatment group had significantly more improvements in angina pecto- ris symptoms, traditional Chinese medicine syndrome, and levels of low - density lipoprotein cholesterol and high - density lipoprotein cholesterol compared with the control group (P 〈 0. 05 ). Conclusion: Huxinkang tablets can ef- fectively relieve the clinical symptoms of UAP with qi deficiency and phlegm stasis syndrome and regulate blood lip- ids, and have a significant clinical effect.